| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f50209b83948dbdd183d6b736dfa2ddb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9ab3b15c19e39a351cf8165a4b4ad68a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_17e294cdec93ba37a65aaaa8903a4294
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcc2072c8fbc0d145dd939cb09722d78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb9c6b40161bafe7bd55f0b4defcea04 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0635 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0781 |
| filingDate |
1997-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8233ccc69015127a99f55ec482b34d0a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f220267cb61d59ccc323eb78b4f79dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d372c1bbff76e37d1944790ecf3e4000
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_797ca75bf9a8fc8f538831910fc3c190 |
| publicationDate |
1998-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9821314-A3 |
| titleOfInvention |
Method of promoting B-cell proliferation and activation and of modulating the immune system |
| abstract |
We teach a strategy to obtain large quantities of desired APCs, activated B cells, which are superior in their capacity to present tumor protein antigen in a multiadministration protocol. Human B cells can be obtained from peripheral blood in large numbers. These cells can be activated in vitro by coculture with CD40L (CD40-B cells) and an immunosuppressive agent such as cyclosporin A. They can be expanded up to 1 x 103 to 1 x 104 fold in 2 weeks or 1 x 105 to 1 x 106 fold in 2 months. We demonstrate these cells are most efficient APCs comparable to DCs in stimulating allogeneic CD4?+ CD45RA+, CD4+¿, CD45RO+, and CD8+ T cells. In contrast to DCs, CD40-B cells are fully functional even in the presence of immunosuppressive cytokines such as IL-1O and TGFβ. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9528088-B2 |
| priorityDate |
1996-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |